Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort
© 2020 John Wiley & Sons Ltd..
BACKGROUND: Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]). Nucleos(t)ide analogues (NUCs) such as tenofovir or entecavir are associated with a reduction in these complications.
AIM: To compare the impact of tenofovir and entecavir on these outcomes in patients treated for HBV infection and included in the prospective Hepather cohort.
METHODS: All patients with HBV infection who had received tenofovir or entecavir for more than 6 months at or after entry in the ANRS CO22 cohort were selected. Patients with HDV and HCV co-infection or prior liver event were excluded. Incidence rates of events were compared using inverse probability of treatment weighting (IPW).
RESULTS: The cohort included 1800 patients (986 tenofovir and 814 entecavir). Median follow-up was 4.2 years. The incidences of HCC, DC, LT, ACD, LRD and CE were not different between tenofovir- (1.8 (0.9; 3.2), 0.6 (0.2; 1.6), 0.2 (0.0; 0.8), 1.7 (0.8; 3.0), 0.8 (0.2, 1.8) and 4.1 (3.0; 5.4) per 1000 person-years) and entecavir-treated patients (1.6 (0.7; 3.0), 0.7 (0.2; 1.8), 0.2 (0.0; 1.0), 3.0 (1.7, 4.8), 0.5 (0.1; 1.5) and 5.0 (3.3; 7.2)) per 1000 person-years, respectively.
CONCLUSION: The risk of liver-related events or death was not different between tenofovir- and entecavir-treated patients in this large prospective cohort of predominantly non-cirrhotic French patients.
TRIAL REGISTRATION NUMBER: NCT019553458.
| Errataetall: |
CommentIn: Aliment Pharmacol Ther. 2021 Mar;53(5):659. - PMID 33566398 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 53(2021), 5 vom: 15. März, Seite 616-629 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pol, Stanislas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5968Y6H45M |
|---|
| Anmerkungen: |
Date Completed 31.03.2021 Date Revised 31.05.2022 published: Print-Electronic CommentIn: Aliment Pharmacol Ther. 2021 Mar;53(5):659. - PMID 33566398 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.16197 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320270866 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320270866 | ||
| 003 | DE-627 | ||
| 005 | 20231225173223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.16197 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320270866 | ||
| 035 | |a (NLM)33464621 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pol, Stanislas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Aliment Pharmacol Ther. 2021 Mar;53(5):659. - PMID 33566398 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]). Nucleos(t)ide analogues (NUCs) such as tenofovir or entecavir are associated with a reduction in these complications | ||
| 520 | |a AIM: To compare the impact of tenofovir and entecavir on these outcomes in patients treated for HBV infection and included in the prospective Hepather cohort | ||
| 520 | |a METHODS: All patients with HBV infection who had received tenofovir or entecavir for more than 6 months at or after entry in the ANRS CO22 cohort were selected. Patients with HDV and HCV co-infection or prior liver event were excluded. Incidence rates of events were compared using inverse probability of treatment weighting (IPW) | ||
| 520 | |a RESULTS: The cohort included 1800 patients (986 tenofovir and 814 entecavir). Median follow-up was 4.2 years. The incidences of HCC, DC, LT, ACD, LRD and CE were not different between tenofovir- (1.8 (0.9; 3.2), 0.6 (0.2; 1.6), 0.2 (0.0; 0.8), 1.7 (0.8; 3.0), 0.8 (0.2, 1.8) and 4.1 (3.0; 5.4) per 1000 person-years) and entecavir-treated patients (1.6 (0.7; 3.0), 0.7 (0.2; 1.8), 0.2 (0.0; 1.0), 3.0 (1.7, 4.8), 0.5 (0.1; 1.5) and 5.0 (3.3; 7.2)) per 1000 person-years, respectively | ||
| 520 | |a CONCLUSION: The risk of liver-related events or death was not different between tenofovir- and entecavir-treated patients in this large prospective cohort of predominantly non-cirrhotic French patients | ||
| 520 | |a TRIAL REGISTRATION NUMBER: NCT019553458 | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a entecavir |2 NLM | |
| 650 | 7 | |a 5968Y6H45M |2 NLM | |
| 650 | 7 | |a Guanine |2 NLM | |
| 650 | 7 | |a 5Z93L87A1R |2 NLM | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 700 | 0 | |a ANRS/AFEF study group |e verfasserin |4 aut | |
| 700 | 1 | |a Bonnet, Delphine |e investigator |4 oth | |
| 700 | 1 | |a Payssan-Sicart, Virginie |e investigator |4 oth | |
| 700 | 1 | |a Pomes, Chloe |e investigator |4 oth | |
| 700 | 1 | |a Bailly, François |e investigator |4 oth | |
| 700 | 1 | |a Beaudoin, Marjolaine |e investigator |4 oth | |
| 700 | 1 | |a Giboz, Dominique |e investigator |4 oth | |
| 700 | 1 | |a Hartig-Lavie, Kerstin |e investigator |4 oth | |
| 700 | 1 | |a Maynard, Marianne |e investigator |4 oth | |
| 700 | 1 | |a Billaud, Eric |e investigator |4 oth | |
| 700 | 1 | |a Boutoille, David |e investigator |4 oth | |
| 700 | 1 | |a Cavellec, Morane |e investigator |4 oth | |
| 700 | 1 | |a Chevalier, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Hubert, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Goepfert, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Lannes, Adrien |e investigator |4 oth | |
| 700 | 1 | |a Lunel, Françoise |e investigator |4 oth | |
| 700 | 1 | |a Boursier, Jérôme |e investigator |4 oth | |
| 700 | 1 | |a Boyer, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a Giuily, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a Castelnau, Corinne |e investigator |4 oth | |
| 700 | 1 | |a Scoazec, Giovanna |e investigator |4 oth | |
| 700 | 1 | |a Chibah, Aziza |e investigator |4 oth | |
| 700 | 1 | |a Keser, Sylvie |e investigator |4 oth | |
| 700 | 1 | |a Bonardi, Karim |e investigator |4 oth | |
| 700 | 1 | |a Vallet-Pichard, Anaïs |e investigator |4 oth | |
| 700 | 1 | |a Sogni, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Foucher, Juliette |e investigator |4 oth | |
| 700 | 1 | |a Hiriart, Jean-Baptiste |e investigator |4 oth | |
| 700 | 1 | |a Legendre, Amandine |e investigator |4 oth | |
| 700 | 1 | |a Chermak, Faiza |e investigator |4 oth | |
| 700 | 1 | |a Irlès-Depé, Marie |e investigator |4 oth | |
| 700 | 1 | |a Si Ahmed, Si Nafa |e investigator |4 oth | |
| 700 | 1 | |a Ansaldi, Christelle |e investigator |4 oth | |
| 700 | 1 | |a Amara, Nisserine Ben |e investigator |4 oth | |
| 700 | 1 | |a Oules, Valérie |e investigator |4 oth | |
| 700 | 1 | |a Dunette, Jacqueline |e investigator |4 oth | |
| 700 | 1 | |a Anty, Rodolphe |e investigator |4 oth | |
| 700 | 1 | |a Gelsi, Eve |e investigator |4 oth | |
| 700 | 1 | |a Truchi, Régine |e investigator |4 oth | |
| 700 | 1 | |a Luckina, Elena |e investigator |4 oth | |
| 700 | 1 | |a Messaoudi, Nadia |e investigator |4 oth | |
| 700 | 1 | |a Moussali, Joseph |e investigator |4 oth | |
| 700 | 1 | |a De Dieuleveult, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Goin, Héloïse |e investigator |4 oth | |
| 700 | 1 | |a Labarrière, Damien |e investigator |4 oth | |
| 700 | 1 | |a Potier, Pascal |e investigator |4 oth | |
| 700 | 1 | |a Si Ahmed, Si Nafa |e investigator |4 oth | |
| 700 | 1 | |a Grando-Lemaire, Véronique |e investigator |4 oth | |
| 700 | 1 | |a Nahon, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Brulé, Séverine |e investigator |4 oth | |
| 700 | 1 | |a Monard, Rym |e investigator |4 oth | |
| 700 | 1 | |a Jezequel, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Brener, Audrey |e investigator |4 oth | |
| 700 | 1 | |a Laligant, Anne |e investigator |4 oth | |
| 700 | 1 | |a Rabot, Aline |e investigator |4 oth | |
| 700 | 1 | |a Renard, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Baumert, Thomas F |e investigator |4 oth | |
| 700 | 1 | |a Dofföel, Michel |e investigator |4 oth | |
| 700 | 1 | |a Mutter, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Simo-Noumbissie, Pauline |e investigator |4 oth | |
| 700 | 1 | |a Razi, Esma |e investigator |4 oth | |
| 700 | 1 | |a Barraud, Hélène |e investigator |4 oth | |
| 700 | 1 | |a Bensenane, Mouni |e investigator |4 oth | |
| 700 | 1 | |a Nani, Abdelbasset |e investigator |4 oth | |
| 700 | 1 | |a Hassani-Nani, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Bernard, Marie-Albertine |e investigator |4 oth | |
| 700 | 1 | |a Pageaux, Georges-Philippe |e investigator |4 oth | |
| 700 | 1 | |a Bismuth, Michael |e investigator |4 oth | |
| 700 | 1 | |a Caillo, Ludovic |e investigator |4 oth | |
| 700 | 1 | |a Faure, Stéphanie |e investigator |4 oth | |
| 700 | 1 | |a Ripault, Marie Pierre |e investigator |4 oth | |
| 700 | 1 | |a Bureau, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Launay, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Peron, Jean Marie |e investigator |4 oth | |
| 700 | 1 | |a Robic, Marie Angèle |e investigator |4 oth | |
| 700 | 1 | |a Tarallo, Léa |e investigator |4 oth | |
| 700 | 1 | |a Faure, Marine |e investigator |4 oth | |
| 700 | 1 | |a Froissart, Bruno |e investigator |4 oth | |
| 700 | 1 | |a Hilleret, Marie-Noelle |e investigator |4 oth | |
| 700 | 1 | |a Zarski, Jean-Pierre |e investigator |4 oth | |
| 700 | 1 | |a Goria, Odile |e investigator |4 oth | |
| 700 | 1 | |a Grard, Victorien |e investigator |4 oth | |
| 700 | 1 | |a Montialoux, Hélène |e investigator |4 oth | |
| 700 | 1 | |a François, Muriel |e investigator |4 oth | |
| 700 | 1 | |a Ouedraogo, Christian |e investigator |4 oth | |
| 700 | 1 | |a Pauleau, Christelle |e investigator |4 oth | |
| 700 | 1 | |a Varault, Anne |e investigator |4 oth | |
| 700 | 1 | |a Andreani, Tony |e investigator |4 oth | |
| 700 | 1 | |a Angoulevant, Bénédicte |e investigator |4 oth | |
| 700 | 1 | |a Chevance, Azeline |e investigator |4 oth | |
| 700 | 1 | |a Serfaty, Lawrence |e investigator |4 oth | |
| 700 | 1 | |a Antonini, Teresa |e investigator |4 oth | |
| 700 | 1 | |a Coilly, Audrey |e investigator |4 oth | |
| 700 | 1 | |a Duclos Vallée, Jean-Charles |e investigator |4 oth | |
| 700 | 1 | |a Tateo, Mariagrazia |e investigator |4 oth | |
| 700 | 1 | |a Bonny, Corinne |e investigator |4 oth | |
| 700 | 1 | |a Brigitte, Chanteranne |e investigator |4 oth | |
| 700 | 1 | |a Lamblin, Géraldine |e investigator |4 oth | |
| 700 | 1 | |a Muti, Léon |e investigator |4 oth | |
| 700 | 1 | |a Babouri, Abdenour |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 53(2021), 5 vom: 15. März, Seite 616-629 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2021 |g number:5 |g day:15 |g month:03 |g pages:616-629 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.16197 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2021 |e 5 |b 15 |c 03 |h 616-629 | ||